...
首页> 外文期刊>International journal of clinical pharmacology and therapeutics >Impact of comorbidities on the treatment of atopic dermatitis in clinical practice
【24h】

Impact of comorbidities on the treatment of atopic dermatitis in clinical practice

机译:临床上合并症对特应性皮炎治疗的影响

获取原文
获取原文并翻译 | 示例
           

摘要

Background and aim: Atopic dermatitis is often associated with atopic comorbidities such as allergic rhinitis, allergic asthma and food allergy. The aim of the present study was to analyze treatment data pertaining to atopic dermatitis patients in Germany with regard to the presence of other atopic comorbidities in the primary care and to investigate whether the presence of atopic codiagnoses has an impact on the treatment of atopic dermatitis (AD) patients. Methods: We used data from the Disease Analyzer database (IMS HEALTH, Germany) including 1,631 physicians (general practitioners, dermatologists and pediatricians) and 3.3 million patients. 39,642 (7.5%) of these patients were treated by dermatologists, 17,124 (5.2%) by pediatricians and 15,774 (0.9%) by general practitioners and had a documented diagnosis of atopic dermatitis. Results: 46.4% of AD patients treated by general practitioners, 42.5% by dermatologists and 32.0% by pediatricians were codiagnosed with one defined atopic diseases (allergic asthma, urticaria, allergic rhinitis and food allergy). In patients without AD, the proportion of atopic diseases was significantly smaller (41.4% for those treated by general practitioners, 38.4% for those treated by dermatologists, 26.4% for those treated by pediatricians). AD patients with another atopic comorbidity received topical corticosteroids (CS) (42.5%) more frequently than those without comorbidity (46.4% vs. 41.4% for patients treated by general practitioners, 42.5% vs. 38.4% for patients treated by dermatologists, 32.0% vs. 26.4% for patients treated by pediatricians). The general practitioners and pediatricians prescribed systemic corticosteroids to 13.2% and 7.8% of AD patients with additional atopic diseases, while the rate was only 5.1% and 3.0% in patients without comorbidities. Conclusion: In AD patients, the share of patients diagnosed with atopic diseases is significantly higher than in patients without AD. AD outpatients with concomitant atopic comorbidities receive topical, but also systemic corticosteroid prescriptions more frequently.
机译:背景与目的:特应性皮炎通常与特应性合并症相关,例如过敏性鼻炎,过敏性哮喘和食物过敏。本研究的目的是分析与德国特应性皮炎患者有关的基本治疗中是否存在其他特应性合并症的治疗数据,并调查特应性联合诊断的存在是否对特应性皮炎的治疗产生影响( AD)患者。方法:我们使用了疾病分析器数据库(德国IMS HEALTH,德国)中的数据,其中包括1,631位医生(全科医生,皮肤科医生和儿科医生)和330万患者。这些患者中有39,642(7.5%)位由皮肤科医生治疗,17,124位(5.2%)由儿科医生治疗,15,774位(0.9%)由普通科医生治疗,并且已被诊断为特应性皮炎。结果:全科医师治疗的AD患者中有46.4%,皮肤科医生占42.5%,儿科医生占32.0%,并被诊断为一种特应性疾病(过敏性哮喘,荨麻疹,过敏性鼻炎和食物过敏)。在没有AD的患者中,特应性疾病的比例明显较小(全科医生治疗的比例为41.4%,皮肤科医生治疗的比例为38.4%,儿科医生的比例为26.4%)。患有另一位特应性合并症的AD患者接受局部皮质类固醇(CS)的比例(42.5%)比无合并症的全科医师接受治疗的比例更高(46.4%vs. 41.4%,经皮肤科医师治疗的患者分别为42.5%和38.4%,32.0%相比,由儿科医生治疗的患者为26.4%)。全科医生和儿科医生对患有特应性疾病的AD患者开出全身性皮质类固醇激素的比例分别为13.2%和7.8%,而无合并症的患者中该比例仅为5.1%和3.0%。结论:在AD患者中,被诊断为特应性疾病的患者所占的比例明显高于没有AD的患者。患有特应性合并症的AD门诊患者会更频繁地接受局部用药,但也接受全身性皮质类固醇处方。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号